Skip to content
value.today
InspireMD, Inc. logo

InspireMD, Inc.

NSPR
$24 Mmarket cap on Oct 30, 2026-56.5% since Jan 2024
Compare
World rank
#23,718
Revenue
$9 M
For year ending December-2025
Net income
$-49 M
-543.3% margin
SEC filing
Employees
127
As of December 31, 2025
SEC filing

InspireMD, Inc. in brief

InspireMD, Inc. is a listed company in the Medical Devices industry, based in Israel. Its market value was $24 M on 30 October 2026, which makes it the 23,718th largest listed company in the world and the 253rd largest in Israel on this site. In the year to December 2025 it had sales of $9 M and a net loss of $49 M. It employs about 127 people and Marvin Slosman is its chief executive. By market, the largest shares of its 2025 sales came from USA (16%), Germany (14%) and Italy (14%). Its shares trade under the symbol NSPR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About InspireMD, Inc.

We are a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. Our portfolio includes two commercial products based on our proprietary CGuard carotid stent technology, designed to provide market-leading embolic protection during and after stenting procedures. A stent is an expandable scaffold-like metallic device placed in an artery to widen the lumen and restore blood flow.

Our first product, the CGuard Carotid Embolic Prevention System, integrates a self-expanding nitinol stent with a MicroNet mesh sleeve as a single device for carotid artery revascularization. In January 2024, we received CE Mark recertification for CGuard EPS under the EU Medical Device Regulation. Our CGuard EPS previously held CE Mark approval under the former Medical Device Directive. CGuard EPS is marketed in over 30 countries outside the United States through a network of distributors.

From the company's annual report filed with the US SEC: read the report

InspireMD, Inc. timeline

3 events, 2009–2025
  1. 2009
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2011
  4. ✎
    Renamed InspireMD, Inc.
    Formerly Saguaro Resources, Inc..
  5. 2025
  6. 💰
    Record revenue of $9 million
    FY2025, the highest of the 8 years on record.

Events of InspireMD, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$19 M$37 M$56 M$75 M2020202120222023202420252026

World rank over time

▲ up 4,004 places since 2020
2020-01-01: #27738#27,73820202021-01-01: #24031#24,03120212022-01-07: #30461#30,46120222022-12-25: #31946#31,94620222023-07-30: #23569#23,56920232024-01-05: #24407#24,40720242026-03-08: #10514#10,51420262026-08-01: #19907#19,90720262026-10-14: #23913#23,91320262026-10-30: #23734#23,7342026

Rank in Israel: #399 (Jan 2020) · #361 (Jan 2021) · #451 (Jan 2022) · #425 (Dec 2022) · #298 (Jul 2023) · #315 (Jan 2024) · #36 (Mar 2026) · #239 (Aug 2026) · #253 (Oct 2026) · #253 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.2×
Price / book
0.4×
Free cash flow yield
-150.9%
Net margin (TTM)
-484.1%
Operating margin
-552.4%
Return on equity
-95.1%
Liabilities / assets
20.5%
Net debt
$-2M
Revenue growth
+28.1%
R&D / revenue
167.0%
Revenue per employee
$71 K
Profit per employee
$-384 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $4M, net income $-7M$4MFY18Fiscal year ending Dec 2019: revenue $4M, net income $-10M$4MFY19Fiscal year ending Dec 2020: revenue $2M, net income $-11M$2MFY20Fiscal year ending Dec 2021: revenue $5M, net income $-15M$5MFY21Fiscal year ending Dec 2022: revenue $5M, net income $-18M$5MFY22Fiscal year ending Dec 2023: revenue $6M, net income $-20M$6MFY23Fiscal year ending Dec 2024: revenue $7M, net income $-32M$7MFY24Fiscal year ending Dec 2025: revenue $9M, net income $-49M$9MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$9M+28.1%$-50M$-49M-543.3%
Dec 2024$7M+13.1%$-34M$-32M-456.5%
Dec 2023$6M+19.9%$-21M$-20M-321.3%
Dec 2022$5M+14.9%$-19M$-18M-357.6%
Dec 2021$5M+81.5%$-15M$-15M-331.6%
Dec 2020$2M-33.3%$-10M$-11M-425.0%
Dec 2019$4M+3.3%$-10M$-10M-269.9%
Dec 2018$4M—$-8M$-7M-201.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-35M$2M$-37M$-0.76—
Dec 2024$-22M$1M$-23M$-0.76—
Dec 2023$-16M$0M$-17M$-0.82—
Dec 2022$-16M$0M$-16M$-2.35—
Dec 2021$-13M$0M$-14M$-2.03—
Dec 2020$-9M$0M$-9M$-6.97—
Dec 2019$-10M$0M$-10M$-4.80—
Dec 2018$-8M$0M$-8M$-16.67—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$11M
Net income, trailing 12 months
$-52M
RevenueNet income
Three months to Sep 2024: revenue $2M, net income $-8M$2MSep ’24Three months to Dec 2024 (from the annual report): revenue $2M, net income $-9M$2MDec ’24Three months to Mar 2025: revenue $2M, net income $-11M$2MMar ’25Three months to Jun 2025: revenue $2M, net income $-13M$2MJun ’25Three months to Sep 2025: revenue $3M, net income $-13M$3MSep ’25Three months to Dec 2025 (from the annual report): revenue $3M, net income $-12M$3MDec ’25Three months to Mar 2026: revenue $3M, net income $-14M$3MMar ’26Three months to Jun 2026: revenue $2M, net income $-14M$2MJun ’26

Latest quarter to Jun 2026: revenue $2M (-0.6% on a year earlier), net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of InspireMD, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$9 M
Operating income
$-50 M
Net income
$-49 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$69 M
Total liabilities
$14 M
Total equity
$55 M

As of December-2025

Top 39 institutional investors in InspireMD, Inc.#

As of Sep 30, 2026
39 institutions held 21.9 M shares (about 47.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 45.1%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in InspireMD, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Rosalind Advisors, Inc.3,905,7430 (0.00%)8.40%$3 MNov 16, 2026
2Aberdeen Group plc3,698,3640 (0.00%)7.96%$2 MNov 10, 2026
3Nantahala Capital Management, LLC3,376,484-3,376,484 (-50.00%)7.26%$2 MNov 13, 2026
4Orbimed Advisors LLC3,133,4050 (0.00%)6.74%$2 MNov 16, 2026
5Parkman Healthcare Partners LLC2,416,5180 (0.00%)5.20%$2 MNov 16, 2026
6Marshall Wace, LLP1,860,4050 (0.00%)4.00%$1 MNov 13, 2026
7Soleus Capital Management, L.P.1,045,7080 (0.00%)2.25%$1 MNov 16, 2026
8Velan Capital Investment Management LP924,680+776,542 (+524.20%)1.99%$1 MNov 16, 2026
9Ingalls & Snyder LLC362,550-6,250 (-1.69%)0.78%$0 MNov 12, 2026
10Affiance Financial, LLC250,3700 (0.00%)0.54%$0 MOct 15, 2026
11UBS Group AG133,653+128,339 (+2415.11%)0.29%$0 MNov 10, 2026
12BlackRock, Inc.117,708-5,285 (-4.30%)0.25%$0 MNov 13, 2026
13Creative Planning108,9640 (0.00%)0.23%$0 MNov 2, 2026
14Schonfeld Strategic Advisors LLC100,201+926 (+0.93%)0.22%$0 MNov 16, 2026
15Renaissance Technologies LLC87,892-24,940 (-22.10%)0.19%$0 MNov 12, 2026
16Courier Capital LLC30,0000 (0.00%)0.06%$0 MOct 19, 2026
17Mesirow Financial Investment Management, Inc.30,0000 (0.00%)0.06%$0 MNov 5, 2026
18Centiva Capital, LP27,180-16,943 (-38.40%)0.06%$0 MNov 13, 2026
19Vestia Personal Wealth Advisors24,4250 (0.00%)0.05%$0 MOct 20, 2026
20Millennium Management LLC21,760-15,917 (-42.25%)0.05%$0 MNov 16, 2026
21XTX Topco Ltd21,080-27,949 (-57.01%)0.05%$0 MNov 16, 2026
22Jane Street Group, LLC20,402New0.04%$0 MNov 12, 2026
23Morgan Stanley20,371-8,000 (-28.20%)0.04%$0 MNov 13, 2026
24Cambridge Investment Research Advisors, Inc.20,116-20,216 (-50.12%)0.04%$0 MNov 2, 2026
25HRT Financial LP19,346-40,408 (-67.62%)0.04%$0 MNov 13, 2026
Show all 39: investors 26 to 39
Institutional investors 26 to 39 in InspireMD, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Susquehanna International Group, LLP19,100-1,494 (-7.25%)0.04%$0 MNov 16, 2026
27Citadel Advisors LLC18,916New0.04%$0 MNov 16, 2026
28LPL Financial LLC18,6210 (0.00%)0.04%$0 MNov 6, 2026
29Osaic Holdings, Inc.15,9520 (0.00%)0.03%$0 MNov 12, 2026
30Avestar Capital, LLC15,0000 (0.00%)0.03%$0 MOct 28, 2026
31Pallas Capital Advisors LLC11,0000 (0.00%)0.02%$0 MNov 12, 2026
32McKinley Carter Wealth Services, Inc.10,0000 (0.00%)0.02%$0 MOct 16, 2026
33BFC Planning, Inc.8,0000 (0.00%)0.02%$0 MNov 13, 2026
34Farther Finance Advisors, LLC1,0000 (0.00%)0.00%$0 MOct 8, 2026
35Citigroup Inc400+399 (+39900.00%)0.00%$0 MNov 4, 2026
36Royal Bank Of Canada2470 (0.00%)0.00%$0 MNov 16, 2026
37Tower Research Capital LLC (TRC)34New0.00%$0 MNov 16, 2026
38Harbour Investments, Inc.14New0.00%$0 MNov 9, 2026
39Caitong International Asset Management Co., Ltd10 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding InspireMD, Inc.#

6 funds hold shares worth $3 M. Since their previous reports 5 added shares and 0 sold, buying $0 M net.
Mutual funds holding InspireMD, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 abrdn Healthcare Investorsabrdn Inc.1.74 M$1 M—0.09%+16%Jun 30, 2026
🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc.1.26 M$1 M—0.11%+19%Jun 30, 2026
🇺🇸 abrdn World Healthcare Fundabrdn Inc.695,460$0 M—0.09%+14%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors114,832$0 M—<0.01%+52%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC18,244$0 M—<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC8,161$0 M—<0.01%+51%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at InspireMD, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$858 K
19 purchases, 6 insiders
Sold, 12 months
$127 K
12 sales, 1 insider
Net, 12 months
$732 K
open market only
Insiders on file
22
since
$455 K-$96 K$0Nov 2023: bought $127 K (1 trades), sold $0 (0 trades)Nov 23Jan 2025: bought $0 (0 trades), sold $57 K (5 trades)Feb 2025: bought $0 (0 trades), sold $67 K (3 trades)FebMay 2025: bought $0 (0 trades), sold $38 K (4 trades)Jul 2025: bought $250 K (4 trades), sold $0 (0 trades)JulNov 2025: bought $22 K (1 trades), sold $0 (0 trades)Dec 2025: bought $37 K (3 trades), sold $0 (0 trades)DecJan 2026: bought $0 (0 trades), sold $96 K (9 trades)Feb 2026: bought $0 (0 trades), sold $8 K (2 trades)FebMay 2026: bought $366 K (11 trades), sold $23 K (1 trades)Nov 2026: bought $455 K (5 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
InspireMD, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gary S. RoubinDirectorBuy+153,846$0.650$100 K988,324Form 4
filed Marvin SlosmanCEO and President, DirectorBuy+46,154$0.650$30 K3.60 MForm 4
filed Michael BermanDirectorBuy+76,923$0.650$50 K429,509Form 4
filed Michael A. LawlessChief Financial OfficerBuy+115,385$0.650$75 K807,080Form 4
filed Paul StukaDirectorBuyindirect+307,693$0.650$200 K731,397Form 4
filed Paul StukaDirectorBuy+20,000$0.880$18 K667,871Form 4
filed Shane Thomas GleasonChief Commercial OfficerSell-22,778$1.010$23 K1.05 MForm 4
filed Paul StukaDirectorBuy+5,000$1.150$6 K647,871Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: InspireMD, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
251,530
0.6% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split ; 1-for-4 reverse split

Fails to deliver

  • : 30,020 shares at $0.45
  • : 30,020 shares at $0.47
  • : 30,020 shares at $0.46
  • : 30,020 shares at $0.45
  • : 30,020 shares at $0.45

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

InspireMD, Inc. scorecard#

Passes 7 of the 20 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.4×Price to book 0.4× against Medical Devices's median of 2.5×.
    • ✓Price to sales below its peers' median2.2×Price to sales 2.2× against Medical Devices's median of 2.4×.
    • ✗Free cash flow yield above 5%-150.9%Free cash flow is -150.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year28.1%Revenue up 28.1% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years20.2%20.2% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median20.2%20.2% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-0.76 vs -0.76Diluted EPS -0.76 in fiscal 2025 against -0.76 the year before (report's currency).
    • ✗Net income higher than five years earlier-$49 M-$49 M in fiscal 2025 against -$11 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$49 MNet income -$49 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-552.5%-552.5% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-106.9%-106.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-552.5%-552.5% in fiscal 2025 against -361.9% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities5.7×Current ratio 5.74 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-6.42Z-score -6.42 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year53.4%Diluted shares up 53.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from InspireMD, Inc.'s statements, beside the median of Medical Devices.

InspireMD, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-552.5%-8.2%
Net margin-543.3%-10.4%
Return on equity-106.9%-16.8%
Revenue growth, 3 years a year20.2%10.8%
Revenue growth28.1%10.4%
Free cash flow margin-409.4%-1.9%

3of 8on the Piotroski tests of financial strength

  • Net loss of $49 million, the 14th loss-making year in a row.
  • Free cash flow was negative: -$37 million.
  • The share count rose 53.4% in the year.
  • Revenue has grown 5 years in a row.

InspireMD, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

InspireMD, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue9.07.06.25.24.52.53.73.62.81.9
Cost of revenue6.35.54.44.13.72.43.02.62.21.8
Gross profit2.61.51.81.10.80.10.81.00.60.1
Research and development15148.07.85.22.23.01.51.31.3
Selling and marketing176.13.93.72.92.12.42.22.41.5
General and administrative2115118.47.46.15.24.85.25.0
Operating expenses523523201510118.68.87.8
Operating income−50−34−21−19−15−10−9.8−7.6−8.2−7.6
Interest expense and finance costs————————0.10.7
Other non-operating income (expense)0.91.61.30.3−0.2−0.2−0.2r−0.4——
Income before tax−49−32−20−18−15−11−10−7.2−8.4−8.5
Income tax0.10.10.10.00.00.00.0—0.00.0
Net income including minority interests——————−10−7.7−13−8.5
Net income attributable to shareholders−49−32−20−18−15−11−10−7.2−8.4−8.5
Earnings per share, basic-0.76-0.76-0.82-2.35-2.03-6.97r-4.80-16.67r-34.98-207.72r
Earnings per share, diluted-0.76-0.76-0.82-2.35-2.03-6.97r-4.80-16.67r-34.98-207.72r
Shares, weighted average (basic)6442247.97.3—————
Shares, weighted average (diluted)6442247.97.31.5r2.10.5r0.40.0r
Balance sheet
Cash and cash equivalents8.9199.64.612135.59.43.77.5
Short-term investments451629———————
Receivables2.21.61.81.01.20.50.80.70.60.4
Inventory3.42.62.11.61.11.41.21.10.50.5
Current assets6141442137157.8115.28.6r
Property, plant and equipment3.62.41.10.90.60.40.50.40.50.4
Right-of-use (leased) assets2.82.41.51.61.11.30.9———
Non-current assets7.96.33.53.32.62.42.10.91.00.8r
Total assets6947482540189.9126.19.4
Accounts payable1.31.30.90.70.90.20.60.90.30.6
Debt due within a year—————————2.7
Current liabilities117.76.05.14.33.73.12.92.54.8
Lease liabilities (non-current)2.21.81.01.20.81.00.7———
Non-current liabilities3.53.02.12.21.81.91.40.60.60.6
Total liabilities14118.17.36.25.64.53.53.15.4
Retained earnings−302−254−222−202−183−168−158−148−140−132
Shareholders' equity5536401734125.48.82.74.0
Total liabilities and equity6947482540189.9126.19.4
Shares outstanding4427228.38.33.3r3.938r1.5r0.0r
Cash-flow statement
Depreciation and amortization476280232188r0.20.20.20.10.20.1
Share-based compensation12104.52.41.60.60.30.10.71.0
Cash from operating activities−35−22−16−16−13−9.1−9.8−7.6−8.1−7.5
Capital expenditure−1.7−1.4−0.4−0.5−0.3−0.1−0.3−0.1−0.3−0.0
Cash from investing activities−3113−168.4−22−0.2−0.4−0.0−0.30.1
Debt repaid————————−2.2−2.6
Shares issued1.01.0————6.3166.814
Cash from financing activities561838−0.135166.3134.612
Exchange-rate effect on cash————————0.0−0.0
Change in cash−10.09.35.0−7.4−0.67.1−3.95.7−3.84.3
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What InspireMD, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where InspireMD, Inc. operates: 5 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

InspireMD, Inc.: countries of operation
CountryPresenceRevenue there
🇮🇱 IsraelHeadquarters—
🇺🇸 USA1 office$1 M16%
🇩🇪 Germany$1 M14%
🇮🇹 Italy$1 M14%
🇵🇱 Poland$1 M12%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at InspireMD, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.1 M
Marvin Slosman
Other top executives, average
$1.8 M
the CEO earned 1.7× this
$100 invested is now
$207
InspireMD, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Marvin Slosman$3.1 M$1.3 M$1.8 M$207
2024Marvin Slosman$3.3 M$2.4 M$1.6 M$306
2023Marvin Slosman$3.2 M$5.9 M$1.5 M$327

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at InspireMD, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 11 · Material agreement 3 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

InspireMD, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K
Directors and officers8-K
Bylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K/A
Results announced8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of InspireMD, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$40 MPrivate placement after listing$10 to $50 million18equity, optionsSEC
May 2023$42 MPrivate placement after listing$10 to $50 million18equity, optionsSEC
Jan 2013$3 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Oct 2012$2 MPrivate placement after listingUnder $2 million1equitySEC
Apr 2012$11 MPrivate placement after listing$10 to $50 million6debt, optionsSEC
Mar 2011$2 MNo. 1Under $2 million3optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How InspireMD, Inc. compares in Medical Devices

  • Market cap$24 M · higher than 15% of 142
  • Revenue$9 M · higher than 15% of 155
  • Net margin-484.1% · higher than 3% of 144
  • Revenue growth28.1% · higher than 81% of 104
  • Price / sales2.3× · lower than 62% of 96
  • Price / book0.4× · lower than 99% of 99
  • FCF yield-150.9% · higher than 1% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
InspireMD, Inc.🇮🇱$24 M—-484.1%+28.1%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at InspireMD, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show InspireMD, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about InspireMD, Inc.? Suggest a correction